A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahalom-Ronen, Yfat, Tamir, Hadas, Melamed, Sharon, Politi, Boaz, Shifman, Ohad, Achdout, Hagit, Vitner, Einat B., Israeli, Ofir, Milrot, Elad, Stein, Dana, Cohen-Gihon, Inbar, Lazar, Shlomi, Gutman, Hila, Glinert, Itai, Cherry, Lilach, Vagima, Yaron, Lazar, Shirley, Weiss, Shay, Ben-Shmuel, Amir, Avraham, Roy, Puni, Reut, Lupu, Edith, Bar-David, Elad, Sittner, Assa, Erez, Noam, Zichel, Ran, Mamroud, Emanuelle, Mazor, Ohad, Levy, Haim, Laskar, Orly, Yitzhaki, Shmuel, Shapira, Shmuel C., Zvi, Anat, Beth-Din, Adi, Paran, Nir, Israely, Tomer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745033/
https://www.ncbi.nlm.nih.gov/pubmed/33328475
http://dx.doi.org/10.1038/s41467-020-20228-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745033/
https://www.ncbi.nlm.nih.gov/pubmed/33328475
http://dx.doi.org/10.1038/s41467-020-20228-7

Ejemplares similares